Free Trial
NASDAQ:VERV

Verve Therapeutics Q3 2024 Earnings Report

Verve Therapeutics logo
$11.13 0.00 (0.00%)
As of 07/25/2025

Verve Therapeutics EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.70
Beat/Miss
Beat by +$0.11
One Year Ago EPS
-$0.72

Verve Therapeutics Revenue Results

Actual Revenue
$6.87 million
Expected Revenue
$2.75 million
Beat/Miss
Beat by +$4.12 million
YoY Revenue Growth
+120.20%

Verve Therapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Tuesday, November 5, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Verve Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Monday, August 11, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Verve Therapeutics Earnings Headlines

Verve Therapeutics Announces Merger and Nasdaq Delisting
Critical AI announcement set to ignite AI 2.0
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
See More Verve Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Verve Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verve Therapeutics and other key companies, straight to your email.

About Verve Therapeutics

Verve Therapeutics (NASDAQ:VERV), a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

View Verve Therapeutics Profile

More Earnings Resources from MarketBeat